The hexosamine biosynthesis pathway is a targetable liability in KRAS/LKB1 mutant lung cancer.

"Competing interests: R.J.D. is an advisor for Agios Pharmaceuticals. J.D.M. receives cell line licensing royalties from the NIH and UTSW. The other authors declare no competing interests."

"R.J.D. is supported by the Howard Hughes Medical Institute, the Robert L. Moody, Sr. Faculty Scholar endowment and by grants from the National Cancer Institute (NCI) (R35CA22044901) and the Cancer Prevention and Research Institute of TEXAS (CPRIT) (RP160089). J.K. (UIC) is supported by the NCI (1K22CA226676–01A1), American Lung Association (LCD-614827) and the V Foundation (V2019–022). J.D.M. is supported by the NCI (SPORE P50CA070907) and CPRIT (RP160652). J.K. (UTSW) is supported by NCI (1R01CA196851, SPORE P50CA70907) and the American Cancer Society (RSG-16–090-01-TBG). S.K. was supported by the National Heart, Lung, and Blood Institute (5T32HL098040)."